Braun Michael S, Quirke Philip, Seymour Matthew T
University of Leeds, UK.
Expert Rev Anticancer Ther. 2007 Apr;7(4):489-501. doi: 10.1586/14737140.7.4.489.
Outcomes in colorectal cancer have improved over the last 15 years; this is in part due to the optimization of 5-fluorouracil schedules and the introduction of new and effective chemotherapeutic agents, such as irinotecan and oxaliplatin. However, not all patients respond to these agents and a proportion may suffer severe side effects from particular chemotherapy drugs. These observations have resulted in a concerted research effort to identify markers of chemotherapy efficacy and toxicity. Here we review the evidence for using molecular markers to individualize chemotherapy treatment in colorectal cancer.
在过去15年中，结直肠癌的治疗效果有所改善；这部分归功于5-氟尿嘧啶给药方案的优化以及新型有效化疗药物的引入，如伊立替康和奥沙利铂。然而，并非所有患者对这些药物都有反应，一部分患者可能会因特定化疗药物出现严重副作用。这些观察结果促使人们齐心协力开展研究，以确定化疗疗效和毒性的标志物。在此，我们综述了使用分子标志物实现结直肠癌化疗个体化治疗的证据。
